Stocks › BIIB
BIOGEN INC.
BIIB·Nasdaq·
United States·USD
United States·USD$222.89
-0.70 (-0.31%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
BIIB
BIOGEN INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
BIIBS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of BIIB by members of U.S. Congress · 217 on record · 11 in the last 12 months
Whale Activity
Position changes in BIIB reported for 2026-06-30 by 13 tracked institutional filers
- Increased4
- New1
- Held0
- Decreased3
- Closed1
- No prior filing4
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 16.0M | $3.45B | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 9.7M | $2.09B | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.6M | $1.43B | increased |
| CITADEL ADVISORS LLC | 418.4K | $90.4M | increased |
| CAUSEWAY CAPITAL MANAGEMENT LLC | 278.3K | $60.1M | — |
| Palo Alto Investors LP | 140.3K | $30.3M | — |
| Point72 Asset Management, L.P. | 88.1K | $19.0M | decreased |
| RENAISSANCE TECHNOLOGIES LLC | 77.7K | $16.8M | decreased |
| D. E. Shaw & Co., Inc. | 74.4K | $16.1M | new |
| TWO SIGMA INVESTMENTS, LP | 7,105 | $1.5M | decreased |
| Knott David M Jr | 4,000 | $864K | — |
| Pacer Advisors, Inc. | 1.1M | $243K | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by BIIB insiders, by quarter · Form 4
Recent Insider Transactions
3,337 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Minor LloydDirector · Director | Sale | −593 | $200.96 | $119K | Aug 4, 2026 | Form 4 ↗ |
| Minor LloydDirector · Director | Sale | −593 | $203.34 | $121K | Aug 3, 2026 | Form 4 ↗ |
| HAWKINS WILLIAM ADirector | Grant / award | +1,505 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| SHERWIN STEPHEN ADirector | Grant / award | +1,505 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Rowinsky Eric KDirector | Grant / award | +1,505 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Mantas Jesus BDirector | Grant / award | +1,505 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| LANGER SUSANDirector | Grant / award | +1,505 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Patolawala Monish DDirector | Grant / award | +1,505 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Pangalos Menelas NDirector | Grant / award | +1,505 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Pangalos Menelas NDirector | Option exercise | +2,370 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Minor LloydDirector | Grant / award | +1,505 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Freire Maria CDirector | Grant / award | +2,005 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Keeney AdamHead of Corporate Development | Tax withholding | −455 | $187.06 | $85K | May 1, 2026 | Form 4 ↗ |
| Keeney AdamHead of Corporate Development | Option exercise | +939 | $0.00 | $0 | May 1, 2026 | Form 4 ↗ |
| Godbout SeanChief Accounting Officer | Tax withholding | −54 | $183.78 | $10K | Apr 1, 2026 | Form 4 ↗ |
| Godbout SeanChief Accounting Officer | Option exercise | +181 | $0.00 | $0 | Apr 1, 2026 | Form 4 ↗ |
| Murphy NicoleHead of Pharm Ops and Tech | Purchase | +3 | $195.04 | $585 | Feb 12, 2026 | Form 4 ↗ |
| Singhal PriyaHead of Development | Sale | −2,660 | $199.83 | $532K | Feb 9, 2026 | Form 4 ↗ |
| Viehbacher ChristopherPresident and CEO · Director | Tax withholding | −6,624 | $201.18 | $1.3M | Feb 6, 2026 | Form 4 ↗ |
| Viehbacher ChristopherPresident and CEO · Director | Option exercise | +15.5K | $0.00 | $0 | Feb 6, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding BIIB · SEC Form N-PORT
This section is temporarily unavailable, reload in a minute.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 18.3M shares12.4%
Aug 6, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 18.3M shares12.4%
Aug 6, 2026 · ↗ - Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 16.7M shares11.3%
Jun 5, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 16.7M shares11.3%
Jun 5, 2026 · ↗ - Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 12.8M shares8.7%
May 6, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 12.8M shares8.7%
May 6, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming biogen as client
- FEDERAL STREET STRATEGIES, LLCBIOGEN, INC. · 2026 Q2 · HCR, MMM$50K
Filing ↗ - TODD STRATEGY GROUPBIOGEN, INC. · 2026 Q2 · MMM, HCR$50K
Filing ↗ - BIOGENBIOGEN · 2026 Q2 · HCR, MMM, PHA, TAX$1.1M
Filing ↗ - DLA PIPER LLP (US)BIOGEN, INC. · 2026 Q2 · PHA, CPT, HCR, MED$60K
Filing ↗ - FEDERAL STREET STRATEGIES, LLCBIOGEN, INC. · 2026 Q1 · HCR, MMM$50K
Filing ↗
Government Contracts
Federal awards to BIOGEN INC. · USAspending
No federal contract awards found for BIOGEN INC..
U.S. Patents
Recent USPTO applications naming BIOGEN INC.
No USPTO patent applications found for BIOGEN INC..
Annual Financials
From BIIB's 10-K filings · XBRL
No annual XBRL figures on record for BIIB. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
- 3-for-1Stock splitJan 18, 2001
- 2-for-1Stock splitDec 21, 1999
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 9.01Results of operationsJul 29, 2026
EDGAR ↗ - 8-K · Items 2.02Results of operationsJul 1, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 10, 2026
EDGAR ↗ - 8-K/A · Items 9.01Jun 10, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.01, 2.03, 7.01, 9.01Material agreement · Acquisition or disposition · Direct financial obligationMay 14, 2026
EDGAR ↗
About BIOGEN INC.
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersCAMBRIDGE, MA
IncorporatedDE
SEC CIK0000875045 ↗
Former namesBIOGEN IDEC INC., BIOGEN IDEC INC, IDEC PHARMACEUTICALS CORP / DE